ACTUATE THERAPEUTICS INC. - COMMON STOCK

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

12 11月 2024 08:00:03 条件 Nasdaq GlobeNewswire

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

29 10月 2024 18:39:24 条件 Nasdaq GlobeNewswire

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

23 9月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

16 9月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

11 9月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

09 9月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05 9月 2024 09:10:56 条件 Nasdaq GlobeNewswire

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024

20 8月 2024 09:00:00 条件 Nasdaq GlobeNewswire